Inicio | Área Médicos | Bibliografía



1 Heurteaux C, Widmann C, Moha ou Maati H, Quintard H, Gandin C, Borsotto M, et al. NeuroAiD™: properties for neuroprotection and neurorepair. Cerebrovasc Dis. 2013; 35 Suppl 1:1-7.

2 Moha Ou Maati H, Borsotto M, Chatelain F, Widmann C, Lazdunski M, Heurteaux C. Activation of ATP-sensitive potassium channels as an element of the neuroprotective effects of the traditional Chinese medicine MLC901 against oxygen glucose deprivation. Neuropharmacology. 2012;63(4):692-700.

3 Quintard H, Borsotto M, Veyssiere J, Gandin C, Labbal F, Widmann C, et al. MLC901, a traditional Chinese medicine protects the brain against global ischemia. Neuropharmacology. 2011;61(4):622-31.

4 Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, Lhuillier M, et al. Neuroprotective and neuroproliferative activities of NeuroAiD™ (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology. 2010;58(7):987-1001.


5 Venketasubramanian N, Young SH, Tay SS, Umapathi T, Lao AY, Gan HH, et al. Chinese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy. Cerebrovasc Dis. 2015;39(5-6):309-18.

6 Dib M, Abdul Zahra IK, Chankrachang S, Czlonkowska A, Fedin AI, Manvelyan H et al. NeuroAiD (MLC601, MLC 910): A new Bench-to-Beside Approach to the Treatment of Ischemic Brain Injury. Eur J Med Plants. 2015;5(2):117-26.

7 Chen CL, Venketasubramanian N, Lee CF, Wong KS, Bousser MG; CHIMES Study Investigators. Effects of MLC601 on early vascular events in patients after stroke: The CHIMES study. Stroke, 2013;44(12):3580-3.

8 Chen CL, Young SH, Gan HH, Singh R, Lao AY, Baroque AC 2nd, et al. Chinese medicine NeuroAiD™ efficacy on stroke recovery: a double-blind, placebo-controlled, randomized study. Stroke. 2013;44(8):2093-100.


9 Siddiqui FJ, Venketasubramanian N, Chan ES, Chen C. Effi cacy and safety of MLC601 (NeuroAiD™), a traditional Chinese medicine, in postroke recovery: a systematic review. Cerebrovasc Dis. 2013;35 Suppl 1:8-17.

10 Shahripour RB, Shamsaei G, Pakdaman H, Majdinasab N, Nejad EM, Sajedi SA, et al. The effect of NeuroAiD™ (MLC601) on cerebral blood fl ow velocity in subjects' post brain infarct in the middle cerebral artery territory. Eur J Intern Med. 2011;22(5):509-13.

11 Harandi AA, Abolfazli R, Hatemian A, Ghragozlee K, Ghaffar-Pour M, Karimi M, et al. Safety and effi cacy of MLC601 in Iranian patients after stroke: a double-blind, placebo-controlled clinical trial. Stroke Res Treat. 2011;2011:721613.

12 Ghandehari K, Mood ZI, Ebrahimzadeh S, Picard D, Zhang Y. NeuroAiD (MLC601) versus piracetam in the recovery of post-infarct homonymous hemianopsia. Neural Regen Res. 2011;6(6):418-22.

13 Chen C, Venketasubramanian N, Gan RN, Lambert C, Picard D, Chan BP, et al. Danqi Piantan Jiaonang, a traditional Chinese medicine, in post stroke recovery. Stroke. 2009; 40: 859-63.


14 Shahripour RB, Hemati A, Maleki AH. Randomized trial to assess the long-term safety of NeuroAiD™ among caucasian patients with acute ischemic stroke. Chin J Integr Med. 2014;20(11):812-7.

15 Young SH, Zhao Y, Koh A, Singh R, Chan BP, Chang HM, et al. Safety profi le of MLC601 (NeuroAiD™) in acute ischemic stroke patients: a Singaporean substudy of the Chinese medicine NeuroAiD™ efficacy on stroke recovery study. Cerebrovasc Dis. 2010;30(1):1-6.

16 Gan R, Lambert C, Lianting J, Chan ES, Venketasubramanian N, Chen C, et al. Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients. Cerebrovasc Dis. 2008;25(5):450-6.